Last update 06 Jun 2025

Selinexor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CRM1-nuclear-export-inhibitor, NEXPOVIO, Selinexor
+ [13]
Action
inhibitors
Mechanism
ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors), XPO1 inhibitors(Exportin-1 protein inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (03 Jul 2019),
RegulationPriority Review (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (South Korea), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H11F6N7O
InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N
CAS Registry1393477-72-9

External Link

KEGGWikiATCDrug Bank
D11222Selinexor

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Follicular Lymphoma
Indonesia
05 Mar 2025
Refractory Multiple Myeloma
Macao
06 Dec 2023
Relapse multiple myeloma
Macao
06 Dec 2023
Diffuse large B-cell lymphoma recurrent
Israel
04 Feb 2021
Diffuse large B-cell lymphoma refractory
Israel
04 Feb 2021
Diffuse Large B-Cell Lymphoma
United States
22 Jun 2020
Multiple Myeloma
United States
03 Jul 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 3
China
29 Jan 2023
Relapsing acute myeloid leukemiaPhase 3
China
29 Jan 2023
Endometrial CarcinomaPhase 3
China
27 Oct 2021
Endometrial CarcinomaPhase 3
China
27 Oct 2021
MyelofibrosisPhase 3
United States
11 Mar 2021
MyelofibrosisPhase 3
Belgium
11 Mar 2021
MyelofibrosisPhase 3
Bulgaria
11 Mar 2021
MyelofibrosisPhase 3
Canada
11 Mar 2021
MyelofibrosisPhase 3
Czechia
11 Mar 2021
MyelofibrosisPhase 3
Denmark
11 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
28
vntjaunlmw(noijtlwebw) = gnrjlglcrd cqzfvzcrrr (skaduqzuqz )
Positive
30 May 2025
vntjaunlmw(noijtlwebw) = lgzwomckex cqzfvzcrrr (skaduqzuqz )
Phase 2
60
xjeiurvyhy = jgsmdcouic sovsfwdykx (mnxlaoxcfx, eoxctkopqz - ihwrtucpca)
-
07 Feb 2025
Phase 1
29
gcfadjlrdo(qvaasklfhz) = including 10% with hyponatremia, 7% with neutropenia, and 7% with thromboembolic events. ftsombxghx (bjtcefaofj )
Positive
01 Feb 2025
Phase 1
10
Selinexor 60 mg PO twice weekly + Pembrolizumab
oracpwaejz(mqrjkeukzm) = oegnaelfrr fnizemlcwg (yantjmznxe, 4 - notreached)
Positive
01 Feb 2025
Selinexor 60 mg PO once weekly + Nivolumab and Ipilimumab
oracpwaejz(mqrjkeukzm) = iylvmdyoiv fnizemlcwg (yantjmznxe, 7 - notreached)
Phase 1/2
74
(Arms A+B+C+D+E: Selinexor)
hhoaffbxfd = pgrsihuqym fpmucnexxr (iccnruziux, zspyqtecou - tjasoelmsy)
-
16 Dec 2024
(Arm A: Selinexor + Radiation Therapy)
rcexdncrtl = yktcxcnjon sxugivthud (hjwocyutny, cbtdihwoaj - wucubrrjci)
ASH2024
ManualManual
Phase 2
40
mfndtgslys(gipbtkakxf) = jrottnfczb cxjiubtnig (rqrwvivnza )
Positive
09 Dec 2024
Phase 3
154
pdyuzhjdpm(ekjwffsyxm) = avksyvluja fyabffyjzp (axkizoqkhx )
Positive
09 Dec 2024
pdyuzhjdpm(ekjwffsyxm) = csqnycapkm fyabffyjzp (axkizoqkhx )
Phase 1/2
17
eejwzeupoe(ocxcwarhok) = iunzkxexoc fkatgexmje (abawfbufdf )
Positive
09 Dec 2024
(CPIs exposed pts)
eejwzeupoe(ocxcwarhok) = krykehyrka fkatgexmje (abawfbufdf )
Phase 2
-
zhfwglqlzl(wpzzalnbvw) = Toxicity and tolerability were consistent with previous selinexor trials and generally manageable, with 11% of patients discontinuing treatment early due to adverse events. vfpiphjapu (otvhvtlbrz )
-
08 Dec 2024
Not Applicable
-
Selinexor 60 mg QW
aevzdvwiiv(pyuktnpmsq) = Entire cohort: 54.3%/33.3%, SPd60: 65.0%/25.0%, SPd40: 31.3%/18.8% domrglyuiv (qehczngfxo )
-
07 Dec 2024
Selinexor 40 mg QW
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free